Cwm LLC Sells 178 Shares of Waters Co. (NYSE:WAT)

Cwm LLC reduced its stake in shares of Waters Co. (NYSE:WATGet Rating) by 50.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 173 shares of the medical instruments supplier’s stock after selling 178 shares during the quarter. Cwm LLC’s holdings in Waters were worth $47,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of WAT. Vanguard Group Inc. increased its stake in shares of Waters by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 6,689,208 shares of the medical instruments supplier’s stock valued at $2,076,263,000 after buying an additional 30,274 shares during the period. Wellington Management Group LLP increased its position in Waters by 79.6% in the first quarter. Wellington Management Group LLP now owns 1,504,592 shares of the medical instruments supplier’s stock worth $467,011,000 after purchasing an additional 666,851 shares during the period. Northern Trust Corp raised its holdings in Waters by 0.4% during the 1st quarter. Northern Trust Corp now owns 840,359 shares of the medical instruments supplier’s stock worth $260,839,000 after purchasing an additional 3,187 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Waters by 1.2% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 835,336 shares of the medical instruments supplier’s stock valued at $276,479,000 after purchasing an additional 10,114 shares during the period. Finally, Boston Trust Walden Corp boosted its stake in shares of Waters by 3.0% in the 2nd quarter. Boston Trust Walden Corp now owns 401,101 shares of the medical instruments supplier’s stock valued at $132,757,000 after purchasing an additional 11,794 shares during the last quarter. Institutional investors and hedge funds own 88.58% of the company’s stock.

Waters Trading Up 1.0 %

NYSE WAT opened at $332.04 on Friday. Waters Co. has a one year low of $265.61 and a one year high of $369.00. The company has a debt-to-equity ratio of 3.88, a current ratio of 2.15 and a quick ratio of 1.55. The firm has a market cap of $19.73 billion, a P/E ratio of 28.97, a P/E/G ratio of 3.68 and a beta of 0.91. The stock’s 50-day moving average is $337.72 and its 200-day moving average is $319.80.

Waters (NYSE:WATGet Rating) last announced its quarterly earnings results on Tuesday, November 1st. The medical instruments supplier reported $2.64 earnings per share for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. Waters had a net margin of 23.63% and a return on equity of 189.79%. The firm had revenue of $708.56 million for the quarter, compared to analyst estimates of $680.30 million. Sell-side analysts anticipate that Waters Co. will post 11.92 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Edward Conard sold 1,059 shares of Waters stock in a transaction that occurred on Wednesday, November 30th. The stock was sold at an average price of $334.70, for a total value of $354,447.30. Following the sale, the director now owns 74,224 shares of the company’s stock, valued at approximately $24,842,772.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.77% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on WAT. Barclays dropped their price target on shares of Waters from $345.00 to $340.00 and set an “overweight” rating for the company in a research note on Thursday, October 6th. Wells Fargo & Company raised their price target on Waters from $315.00 to $320.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 2nd. StockNews.com started coverage on Waters in a report on Wednesday, October 12th. They issued a “buy” rating for the company. Robert W. Baird cut their target price on Waters from $348.00 to $317.00 in a research note on Wednesday, November 2nd. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Waters in a research report on Tuesday, December 13th. They set a “hold” rating and a $350.00 target price for the company. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $345.22.

About Waters

(Get Rating)

Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.

Read More

Want to see what other hedge funds are holding WAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Waters Co. (NYSE:WATGet Rating).

Institutional Ownership by Quarter for Waters (NYSE:WAT)

Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.